Asthma Control and Clinical Practice in Hungary 2009

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: May 12, 2009
Last updated: December 3, 2009
Last verified: December 2009
A prospective study led amongst pulmonologists. Patients asthma control level will be evaluated based on GINA guideline criteria. HRQoL measured by Visual analogue scale. Clinical practice: non controlled patients therapy assessed.

Asthma Control Level

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Asthma Control and Clinical Practice in Hungary 2009

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Asthma control level [ Time Frame: 3 times ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Visual Analogue Scale [ Time Frame: 3 times ] [ Designated as safety issue: No ]
  • Routine Therapeutical habits in control maintenance [ Time Frame: 3 times ] [ Designated as safety issue: No ]

Estimated Enrollment: 3000
Study Start Date: April 2009
Study Completion Date: November 2009
Asthmatic patients above 18 y, treated with ICS or bronchodilators


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pulmonology outpatient clinics

Inclusion Criteria:

  • Asthma patients treated with ICS or bronchodilators

Exclusion Criteria:

  • COPD
  • pulmonary cancer
  • pulmonary tuberculosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00900861

  Show 75 Study Locations
Sponsors and Collaborators
Principal Investigator: Zoltan Bartfai, MD PhD Semmelweis University Budapest Pulmonology Clinic
Study Chair: Lilla Szabo AstraZeneca Hungary
Study Director: Eva Gulyas AstraZeneca Hungary
  More Information

Responsible Party: MCMD, AstraZeneca Identifier: NCT00900861     History of Changes
Other Study ID Numbers: NIS-RHU-DUM-2009/1 
Study First Received: May 12, 2009
Last Updated: December 3, 2009
Health Authority: Hungary: National Institute of Pharmacy

Keywords provided by AstraZeneca:
asthma control level
visual analogue scale

Additional relevant MeSH terms:
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases processed this record on May 23, 2016